Epigenetic Mechanisms in the Transfer of Metabolic Disorders: A Comprehensive Review

代谢紊乱转移中的表观遗传机制:一项综合综述

阅读:1

Abstract

Epigenetic modifications, including deoxyribonucleic acid (DNA) methylation, histone modifications, and non-coding ribonucleic acid (ncRNAs), regulate gene expression without altering the DNA sequence and play pivotal roles in the pathogenesis of metabolic disorders (MDs), such as diabetes, obesity, and cardiovascular diseases. This review aims to consolidate the current knowledge on the epigenetic mechanisms underlying MDs, emphasizing histone modifications and ncRNAs. A comprehensive literature search was conducted using the PubMed, Scopus, and Web of Science databases. Studies published between 2000 and 2024 (a few foundational and historical articles were also added) were screened using search terms such as "epigenetics AND metabolic disorders," "DNA methylation AND diabetes," "histone modifications AND obesity," and "non-coding RNA AND cardiovascular diseases." Relevant translational and clinical studies were reviewed to synthesize the existing evidence on the epigenetic regulation of metabolic diseases. Histone modifications, including acetylation, methylation, phosphorylation, and ubiquitination, contribute to metabolic dysregulation by modulating chromatin accessibility and gene transcription. Additionally, ncRNAs, such as microRNAs, long ncRNAs, and circular RNAs, influence metabolic pathways by post-transcriptionally regulating key genes involved in insulin resistance, lipid metabolism, and inflammation. Emerging research highlights the potential of epigenetic biomarkers for early disease detection and prognosis, as well as the therapeutic potential of epigenetic modulators, including histone deacetylase inhibitors and DNA methylation-targeting agents. Despite promising advances, challenges remain in translating epigenetic findings into clinical practice because of inter-individual variability and the complex interplay between genetics and environmental factors. Future research should focus on large-scale, multicenter studies to validate epigenetic biomarkers and develop personalized epigenetic interventions for MDs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。